FIELD: medicine.
SUBSTANCE: method includes carrying out examination at hospitalisation stage. In the process of examination determined are: patient's age in years (X1), patient's height in cm (X2), patient's weight in kg (X3), duration of menstrual cycle in case of intact menstruation in days, in case of pre-menopause period or post-menopause quantity of days equals 0 (X4), number of pregnancies in absolute numbers (X5), number of medical abortions in absolute numbers (X6), predominant protein diet, 1 point - yes, 0 points - no (X7). Index of chemotherapy (EfCT) is determined on the basis of obtained data by formula EfCT= (1.99-0.004*X1-0.008*X2+0.001*X3-0.0009*X4-0.013*X5+0.014*X6-0.057*X7)*100%. 1.99 is a free member of the sum, -0.004; -0.008; +0.001; -0.0009; -0.013; 0.014; -0.057 are coefficients. If EfCT value equals 50% and more, chemotherapy is indicated to patient until molecular type of mammary gland cancer is determined. If EfCT value is smaller than 50%, carrying out chemotherapy is not indicated.
EFFECT: method simplifies and accelerates prediction of efficiency of chemotherapy of mammary gland cancer due to application of indirect signs.
2 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF HORMONE-DEPENDENT BREAST CANCER | 2014 |
|
RU2559152C1 |
METHOD FOR PREDICTION OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH THREE-TIMES NEGATIVE MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2623118C1 |
METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
METHOD OF PREDICTING HIGH RISK OF REGIONAL METASTASIS IN BREAST CANCER | 2023 |
|
RU2816441C1 |
METHOD FOR PREDICTION OF COMPLETE MORPHOLOGICAL REGRESSIONS IN PATIENTS SUFFERING TRIPLE-NEGATIVE RESECTABLE BREAST CANCER | 2014 |
|
RU2560707C1 |
METHOD FOR PREDICTION OF DEGREE OF FULL REGRESSION PROBABILITY DURING NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH LUMINAL MOLECULAR-GENETIC SUBTYPE OF BREAST CANCER | 2016 |
|
RU2632112C1 |
METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
METHOD FOR PREDICTING RISK OF BREAST CANCER PROGRESSION WITH UNDERLYING TAMOXIFEN TAKING INTO ACCOUNT EXPRESSION CHARACTERISTICS OF TUMOUR | 2023 |
|
RU2823488C1 |
Authors
Dates
2015-05-20—Published
2014-07-04—Filed